Desferri-Exochelin, a lipid-soluble, hexadentate iron chelator, effectively removes tissue iron

Translational Research

Volumn 148, Issue 2, 2006, Pages 63-71

  Hodges, Yvonne K ^a   Weinberger, Howard D ^a   Stephens, Janet ^b   Horwitz, Marcus A ^c   Horwitz, Lawrence D ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b Exempla Saint Joseph Hospital   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

772 SM; DESFERRIEXOCHELIN; IRON CHELATING AGENT; IRON DEXTRAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATOMIC ABSORPTION; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG UPTAKE; EXPERIMENTAL MODEL; HEART; IRON OVERLOAD; IRON URINE LEVEL; LIPID SOLUBILITY; LIVER; LIVER LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TISSUE LEVEL; URINARY EXCRETION;

EID: 33746564070     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2006.03.003     Document Type: Article

References (24)

1. Borgna-Pignatti C., Cappellini P., De Stefano P., Del Vecchio G.C., Forni G.L., Gamberini M.R., et al. Survival and complications in thalassemia. Ann N Y Acad Sci 1054 (2005) 40-47
2. Cunningham M.J., and Nathan D.G. New developments in iron chelators. Curr Opin Hematol 12 (2005) 129-134
3. Obejero-Paz C.A., Yang T., Dong W.-Q., Levy M.N., Brittenham G.M., Kuryshev Y.A., et al. Deferoxamine promotes survival and prevents electrocardiographic abnormalities in the gerbil model of iron-overload cardiomyopathy. J Lab Clin Med 141 (2003) 121-130
4. Graf E., Mahoney J.R., Bryant R.G., and Eaton J.W. Iron-catalyzed hydroxyl formation. stringent requirement for free iron coordination site. J Biol Chem 259 (1984) 3620-3624
5. Chaston T.B., and Richardson D.R. Iron chelators for the treatment of iron overload disease. relationship between structure, redox activity, and toxicity. Am J Hematol 73 (2003) 200-210
6. Lloyd J.B., Cable H., and Rice-Evans C. Evidence that desferrioxamine cannot enter cells by passive diffusion. Biochem Pharmacol 41 (1991) 1361-1363
7. Summers M.R., Jacobs A., Tudway B., Perera P., and Ricketts C. Studies in desferioxamine and ferrioxamine metabolism in normal and iron-loaded subjects. Br J Haematol 42 (1979) 547-555
8. Propper R.D., Cooper B., Rufo R.R., Nienhuis A.W., Anderson W., Bunn H.F., et al. Continuous subcutaneous administration of deferoxamine in patients with iron overload. N Eng J Med 297 (1977) 418-423
9. Gobin J., Moore C.H., Reeve Jr. J.R., Wong D.K., Gibson B.W., and Horwitz M.A. Iron acquisition by Mycobacterium tuberculosis. isolation and characterization of a family of iron-binding exochelins. Proc Natl Acad Sci USA 92 (1995) 5189-5193
10. Horwitz L.D., Sherman N.A., Kong Y., Pike A.W., Gobin J., Fennessey P.V., et al. Lipophilic siderophores of Mycobacterium tuberculosis prevent cardiac reperfusion injury. Proc Natl Acad Sci USA 95 (1998) 5263-5268
11. Hodges Y.K., Antholine W.E., and Horwitz L.D. Effect on ribonucleotide reductase of novel lipophilic iron chelators. the desferri-exochelins. Biochem Biophys Res Commun 315 (2004) 595-598
12. Kurien B.T., Everds N.E., and Scofield R.H. Experimental animal urine collection. a review. Lab Anim 38 (2004) 333-361
13. Fish W.W. Rapid colorimetric micromethod for the quantitation of complexed iron in biological samples. Methods Enzymol 158 (1988) 357-364
14. Bisognano J.D., Weinberger H.D., Bohlmeyer T.J., Pende A., Raynolds M.V., Sastravaha A., et al. Myocardial-directed overexpression of the human β1-adrenergic receptor in transgenic mice. J Mol Cell Cardiol 32 (2000) 817-830
15. Freeman K., Colon-Rivera C., Olsson M.C., Moore R.L., Weinberger H.D., Grupp I.L., et al. Progression from hypertrohic to dilated cardiomyopathy in mice that express a mutant myosin transgene. Am J Physiol 280 (2001) H151-H159
16. Eybl V., Kotyzova D., Kolek M., Koutensky J., and Nielsen P. The influence of deferiprone (L1) and deferoxamine on iron and essential element tissue level and parameters of oxidative status in dietary iron-loaded mice. Toxicol Lett 128 (2002) 169-175
17. Cunningham M.J., and Nathan D.G. New developments in iron chelators. Curr Opin Hematol 12 (2005) 129-135
18. Hoffbrand A.V., Cohen A., and Hershko C. Role of deferiprone in chelation therapy for transfusional overload. Blood 102 (2003) 17-24
19. Cappelini M.D. Iron-chelating therapy with the new oral agent ICL670 (Exjade®). Best practice and research. Clin Haematol 18 (2005) 289-298
20. Gobin J., and Horwitz M.A. Exochelins of Mycobacterium tuberculosis remove iron from human iron-binding proteins and donate iron to mycobactins in the M. tuberculosis cell wall. J Exp Med 183 (1996) 1527-1532
21. Livrea M.A., Tesoriere L., Pintaudi A.M., Calabrese A., Maggio A., et al. Oxidative stress and antioxidant status in β-thalassemia major. iron overload and depletion of lipid-soluble antioxidants. Blood 88 (1996) 3608-3614
22. Chen K., Suh J., Carr A.C., Morrow J.D., Zeind J., and Frei B. Vitamin C suppresses oxidative lipid damage in vivo, even in the presence of iron overload. Am J Physiol Endocrinol Metab 279 (2000) E1406-E1412
23. Bartfay W., Dawood F., Wen W.H., Lehotay D.C., Hou D., Bartfay E., et al. Cardiac function and cytotoxic aldehyde production in a murine model of chronic iron-overload. Cardiovasc Res 43 (1999) 892-900
24. Brittenham G.M. Iron chelators and iron toxicity. Alcohol 30 (2003) 151-158